Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Migraine Disorders | 78 | 2024 | 1713 | 9.050 |
Why?
|
Headache | 30 | 2022 | 1263 | 4.730 |
Why?
|
Tryptamines | 15 | 2018 | 93 | 3.010 |
Why?
|
Serotonin Receptor Agonists | 15 | 2017 | 151 | 2.920 |
Why?
|
Editorial Policies | 7 | 2016 | 458 | 2.220 |
Why?
|
Analgesics | 14 | 2013 | 1071 | 1.960 |
Why?
|
Headache Disorders | 7 | 2020 | 152 | 1.940 |
Why?
|
Cluster Headache | 8 | 2017 | 54 | 1.890 |
Why?
|
Periodicals as Topic | 9 | 2020 | 1465 | 1.520 |
Why?
|
Clinical Trials as Topic | 14 | 2018 | 8052 | 1.450 |
Why?
|
Sumatriptan | 5 | 2018 | 66 | 1.340 |
Why?
|
Awards and Prizes | 3 | 2023 | 365 | 1.320 |
Why?
|
Headache Disorders, Secondary | 2 | 2019 | 34 | 1.220 |
Why?
|
Cost of Illness | 4 | 2020 | 1951 | 1.180 |
Why?
|
Publishing | 10 | 2022 | 837 | 1.100 |
Why?
|
State Medicine | 2 | 2017 | 219 | 0.980 |
Why?
|
Calcitonin Gene-Related Peptide | 4 | 2024 | 328 | 0.950 |
Why?
|
Vasoconstrictor Agents | 3 | 2018 | 656 | 0.890 |
Why?
|
Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2024 | 108 | 0.880 |
Why?
|
Information Dissemination | 5 | 2021 | 1143 | 0.850 |
Why?
|
General Practice | 2 | 2017 | 101 | 0.830 |
Why?
|
Barbiturates | 4 | 2015 | 113 | 0.810 |
Why?
|
Research Report | 2 | 2015 | 369 | 0.800 |
Why?
|
Nonprescription Drugs | 2 | 2013 | 119 | 0.770 |
Why?
|
Antibodies, Monoclonal | 4 | 2019 | 9262 | 0.760 |
Why?
|
Neurology | 3 | 2020 | 786 | 0.760 |
Why?
|
Migraine with Aura | 3 | 2010 | 204 | 0.750 |
Why?
|
Placebo Effect | 3 | 2020 | 517 | 0.730 |
Why?
|
Access to Information | 2 | 2014 | 317 | 0.720 |
Why?
|
Oxazolidinones | 3 | 2005 | 98 | 0.680 |
Why?
|
Mind-Body Therapies | 2 | 2014 | 294 | 0.680 |
Why?
|
Menstruation | 4 | 2006 | 310 | 0.670 |
Why?
|
Authorship | 2 | 2020 | 289 | 0.670 |
Why?
|
Tension-Type Headache | 4 | 2010 | 76 | 0.660 |
Why?
|
Pain Measurement | 5 | 2013 | 3583 | 0.650 |
Why?
|
Serotonin Syndrome | 1 | 2018 | 18 | 0.610 |
Why?
|
Humans | 153 | 2024 | 768171 | 0.560 |
Why?
|
Personnel Management | 1 | 2016 | 54 | 0.540 |
Why?
|
Contraceptives, Oral, Combined | 3 | 2005 | 118 | 0.520 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2018 | 496 | 0.510 |
Why?
|
Peer Review, Research | 2 | 2020 | 344 | 0.510 |
Why?
|
Drug Industry | 3 | 2015 | 791 | 0.500 |
Why?
|
Drug and Narcotic Control | 1 | 2016 | 145 | 0.500 |
Why?
|
Conflict of Interest | 2 | 2015 | 556 | 0.480 |
Why?
|
Evidence-Based Medicine | 9 | 2021 | 3706 | 0.480 |
Why?
|
Health Services Misuse | 2 | 2015 | 246 | 0.470 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2017 | 348 | 0.470 |
Why?
|
Publication Bias | 1 | 2015 | 158 | 0.470 |
Why?
|
Qualitative Research | 2 | 2016 | 3140 | 0.470 |
Why?
|
Ketoprofen | 1 | 2013 | 8 | 0.460 |
Why?
|
Tromethamine | 1 | 2013 | 31 | 0.460 |
Why?
|
Minority Health | 1 | 2015 | 79 | 0.460 |
Why?
|
Menstrual Cycle | 3 | 2007 | 546 | 0.450 |
Why?
|
Piperidines | 2 | 2018 | 1667 | 0.450 |
Why?
|
Oseltamivir | 1 | 2014 | 76 | 0.440 |
Why?
|
Carbazoles | 2 | 2013 | 230 | 0.440 |
Why?
|
Health Surveys | 3 | 2020 | 4057 | 0.440 |
Why?
|
Primary Health Care | 8 | 2020 | 4746 | 0.430 |
Why?
|
Statistics as Topic | 3 | 2021 | 2357 | 0.430 |
Why?
|
Government Regulation | 2 | 2017 | 525 | 0.420 |
Why?
|
Contraceptives, Oral, Hormonal | 3 | 2017 | 190 | 0.420 |
Why?
|
Health Services | 1 | 2018 | 755 | 0.420 |
Why?
|
Drug Tolerance | 2 | 2011 | 365 | 0.420 |
Why?
|
Guidelines as Topic | 4 | 2021 | 1397 | 0.410 |
Why?
|
Wit and Humor as Topic | 1 | 2012 | 31 | 0.410 |
Why?
|
PubMed | 1 | 2013 | 129 | 0.400 |
Why?
|
Pyrroles | 1 | 2018 | 1124 | 0.400 |
Why?
|
Inappropriate Prescribing | 1 | 2015 | 212 | 0.400 |
Why?
|
Biomedical Research | 6 | 2020 | 3463 | 0.400 |
Why?
|
Patient Satisfaction | 5 | 2021 | 3490 | 0.390 |
Why?
|
Research Design | 5 | 2021 | 6209 | 0.390 |
Why?
|
Diagnostic Errors | 3 | 2017 | 1281 | 0.390 |
Why?
|
Disclosure | 2 | 2015 | 755 | 0.390 |
Why?
|
Fructose | 4 | 2007 | 284 | 0.380 |
Why?
|
Functional Laterality | 1 | 2018 | 2264 | 0.380 |
Why?
|
Patient Care Team | 1 | 2022 | 2523 | 0.370 |
Why?
|
Meditation | 1 | 2014 | 257 | 0.360 |
Why?
|
Musculoskeletal Manipulations | 1 | 2010 | 24 | 0.360 |
Why?
|
Primary Prevention | 1 | 2018 | 1188 | 0.360 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2024 | 10397 | 0.350 |
Why?
|
Prevalence | 12 | 2020 | 15869 | 0.350 |
Why?
|
Benzopyrans | 1 | 2010 | 63 | 0.340 |
Why?
|
Behavior Therapy | 3 | 2012 | 886 | 0.340 |
Why?
|
Hematologic Tests | 1 | 2011 | 239 | 0.340 |
Why?
|
Estrogens | 5 | 2007 | 1536 | 0.320 |
Why?
|
Antidepressive Agents | 2 | 2018 | 2913 | 0.320 |
Why?
|
Interprofessional Relations | 1 | 2015 | 997 | 0.320 |
Why?
|
Health Status Disparities | 1 | 2020 | 1885 | 0.320 |
Why?
|
Anticonvulsants | 3 | 2018 | 1923 | 0.310 |
Why?
|
Urinalysis | 1 | 2011 | 370 | 0.310 |
Why?
|
Physician's Role | 2 | 2013 | 925 | 0.310 |
Why?
|
Female | 65 | 2024 | 397187 | 0.310 |
Why?
|
Population Surveillance | 3 | 2017 | 2596 | 0.300 |
Why?
|
United States | 24 | 2022 | 73039 | 0.290 |
Why?
|
Data Interpretation, Statistical | 1 | 2017 | 2709 | 0.290 |
Why?
|
Societies, Medical | 3 | 2020 | 3968 | 0.290 |
Why?
|
Vascular Diseases | 2 | 2013 | 1162 | 0.290 |
Why?
|
Choice Behavior | 1 | 2013 | 848 | 0.290 |
Why?
|
Health Care Reform | 1 | 2016 | 1256 | 0.280 |
Why?
|
Pyridines | 1 | 2018 | 2894 | 0.270 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1737 | 0.270 |
Why?
|
Butorphanol | 1 | 2006 | 10 | 0.270 |
Why?
|
Pregnancy Complications | 3 | 2007 | 2973 | 0.260 |
Why?
|
Patient Selection | 1 | 2018 | 4260 | 0.260 |
Why?
|
Practice Guidelines as Topic | 8 | 2021 | 7454 | 0.260 |
Why?
|
Mendelian Randomization Analysis | 2 | 2021 | 1040 | 0.250 |
Why?
|
Insurance Coverage | 1 | 2017 | 1946 | 0.250 |
Why?
|
Fellowships and Scholarships | 1 | 2014 | 1135 | 0.250 |
Why?
|
Academic Medical Centers | 2 | 2016 | 2785 | 0.250 |
Why?
|
Drug Approval | 2 | 2018 | 821 | 0.250 |
Why?
|
Nutrition Surveys | 1 | 2013 | 1738 | 0.250 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1328 | 0.240 |
Why?
|
Registries | 4 | 2017 | 8375 | 0.240 |
Why?
|
Stiff-Person Syndrome | 1 | 2005 | 31 | 0.240 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5520 | 0.240 |
Why?
|
Patient Participation | 1 | 2013 | 1447 | 0.230 |
Why?
|
Benzamides | 1 | 2010 | 1379 | 0.230 |
Why?
|
Analgesics, Non-Narcotic | 2 | 2018 | 371 | 0.230 |
Why?
|
Cyclohexanols | 1 | 2004 | 126 | 0.220 |
Why?
|
Dysmenorrhea | 1 | 2005 | 107 | 0.220 |
Why?
|
Rosacea | 1 | 2024 | 60 | 0.220 |
Why?
|
Workplace | 2 | 2020 | 873 | 0.220 |
Why?
|
Postpartum Period | 1 | 2010 | 1197 | 0.220 |
Why?
|
Botulinum Toxins, Type A | 3 | 2018 | 238 | 0.220 |
Why?
|
Checklist | 3 | 2024 | 840 | 0.210 |
Why?
|
Medicine | 2 | 2020 | 945 | 0.210 |
Why?
|
Vascular Headaches | 1 | 2002 | 21 | 0.210 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2006 | 452 | 0.210 |
Why?
|
Triazoles | 3 | 2007 | 904 | 0.210 |
Why?
|
Phenobarbital | 1 | 2003 | 192 | 0.210 |
Why?
|
Influenza, Human | 1 | 2014 | 1541 | 0.210 |
Why?
|
Hospitals, Special | 1 | 2003 | 90 | 0.200 |
Why?
|
Analgesics, Opioid | 3 | 2015 | 3837 | 0.200 |
Why?
|
Adult | 41 | 2024 | 223646 | 0.200 |
Why?
|
Needs Assessment | 3 | 2016 | 1141 | 0.200 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2024 | 640 | 0.190 |
Why?
|
Male | 41 | 2024 | 364731 | 0.190 |
Why?
|
Economics, Medical | 1 | 2022 | 112 | 0.190 |
Why?
|
Antiviral Agents | 1 | 2014 | 3072 | 0.190 |
Why?
|
Double-Blind Method | 11 | 2021 | 12466 | 0.190 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2006 | 465 | 0.190 |
Why?
|
Rehabilitation Centers | 1 | 2003 | 249 | 0.180 |
Why?
|
Terminology as Topic | 4 | 2021 | 1542 | 0.180 |
Why?
|
Botulinum Toxins | 1 | 2002 | 191 | 0.180 |
Why?
|
Health Care Surveys | 2 | 2020 | 2434 | 0.180 |
Why?
|
Drug Labeling | 2 | 2018 | 250 | 0.180 |
Why?
|
Personnel, Hospital | 1 | 2003 | 285 | 0.180 |
Why?
|
Treatment Outcome | 19 | 2021 | 65379 | 0.170 |
Why?
|
Preventive Medicine | 1 | 2002 | 246 | 0.170 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2018 | 4640 | 0.170 |
Why?
|
Politics | 2 | 2017 | 822 | 0.170 |
Why?
|
Education, Medical | 2 | 2017 | 1742 | 0.170 |
Why?
|
Infusions, Intravenous | 1 | 2024 | 2230 | 0.170 |
Why?
|
Drug Combinations | 2 | 2005 | 2089 | 0.160 |
Why?
|
Absenteeism | 1 | 2020 | 247 | 0.160 |
Why?
|
Quality Control | 3 | 2021 | 836 | 0.160 |
Why?
|
Epidemiology | 1 | 2021 | 278 | 0.160 |
Why?
|
Telephone | 1 | 2002 | 630 | 0.160 |
Why?
|
Acne Vulgaris | 1 | 2024 | 352 | 0.160 |
Why?
|
Physicians, Primary Care | 2 | 2016 | 624 | 0.160 |
Why?
|
Iontophoresis | 1 | 2018 | 74 | 0.160 |
Why?
|
Community Health Centers | 1 | 2022 | 469 | 0.160 |
Why?
|
Menopause | 1 | 2007 | 1656 | 0.160 |
Why?
|
Transdermal Patch | 1 | 2018 | 51 | 0.160 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2003 | 628 | 0.150 |
Why?
|
Review Literature as Topic | 2 | 2014 | 297 | 0.150 |
Why?
|
Patients | 1 | 2005 | 908 | 0.150 |
Why?
|
Epidemiologic Research Design | 1 | 2021 | 368 | 0.150 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1667 | 0.150 |
Why?
|
Stroke | 4 | 2017 | 9755 | 0.150 |
Why?
|
Drug Prescriptions | 2 | 2004 | 1668 | 0.150 |
Why?
|
Burns, Chemical | 1 | 2018 | 123 | 0.140 |
Why?
|
Specialization | 1 | 2002 | 779 | 0.140 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3929 | 0.140 |
Why?
|
Indoles | 2 | 2005 | 1836 | 0.140 |
Why?
|
Efficiency | 1 | 2020 | 479 | 0.140 |
Why?
|
Databases, Bibliographic | 2 | 2015 | 128 | 0.140 |
Why?
|
Denmark | 1 | 2019 | 776 | 0.140 |
Why?
|
Formularies as Topic | 1 | 2017 | 94 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 12252 | 0.140 |
Why?
|
Biological Evolution | 1 | 2002 | 1076 | 0.140 |
Why?
|
Professional Competence | 1 | 2020 | 430 | 0.130 |
Why?
|
Workload | 1 | 2002 | 849 | 0.130 |
Why?
|
Marketing | 1 | 2018 | 224 | 0.130 |
Why?
|
Amitriptyline | 1 | 2016 | 112 | 0.130 |
Why?
|
Brain Ischemia | 1 | 2009 | 3007 | 0.130 |
Why?
|
Delphi Technique | 2 | 2017 | 890 | 0.130 |
Why?
|
Middle Aged | 26 | 2021 | 223487 | 0.130 |
Why?
|
Pregnancy | 5 | 2013 | 30255 | 0.130 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2337 | 0.130 |
Why?
|
Prescriptions | 1 | 2018 | 388 | 0.130 |
Why?
|
Electronic Health Records | 3 | 2018 | 4887 | 0.120 |
Why?
|
Hypnotics and Sedatives | 1 | 2003 | 1191 | 0.120 |
Why?
|
England | 1 | 2016 | 533 | 0.120 |
Why?
|
Professional-Patient Relations | 1 | 2020 | 724 | 0.120 |
Why?
|
Federal Government | 1 | 2017 | 266 | 0.120 |
Why?
|
Clinical Protocols | 2 | 2015 | 1443 | 0.120 |
Why?
|
New York | 1 | 2017 | 882 | 0.120 |
Why?
|
Sensation Disorders | 1 | 2015 | 160 | 0.120 |
Why?
|
European Union | 1 | 2015 | 158 | 0.120 |
Why?
|
Cohort Studies | 5 | 2022 | 41753 | 0.120 |
Why?
|
Science | 1 | 2017 | 236 | 0.110 |
Why?
|
Facial Nerve Diseases | 1 | 2014 | 49 | 0.110 |
Why?
|
Spinal Nerves | 1 | 2014 | 92 | 0.110 |
Why?
|
Decision Support Techniques | 1 | 2024 | 2008 | 0.110 |
Why?
|
Aphasia | 1 | 2015 | 193 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2395 | 0.110 |
Why?
|
Mental Disorders | 3 | 2017 | 6873 | 0.110 |
Why?
|
Censuses | 1 | 2014 | 198 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2016 | 4055 | 0.110 |
Why?
|
Diagnosis, Differential | 4 | 2015 | 13013 | 0.110 |
Why?
|
Early Termination of Clinical Trials | 1 | 2013 | 70 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4423 | 0.110 |
Why?
|
Natural Science Disciplines | 1 | 2012 | 3 | 0.110 |
Why?
|
Tablets | 2 | 2005 | 149 | 0.100 |
Why?
|
Pain | 2 | 2005 | 5099 | 0.100 |
Why?
|
Cicatrix | 1 | 2018 | 798 | 0.100 |
Why?
|
Economics | 1 | 2013 | 141 | 0.100 |
Why?
|
Administration, Oral | 3 | 2005 | 4034 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2008 | 1243 | 0.100 |
Why?
|
Academies and Institutes | 1 | 2014 | 326 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5536 | 0.100 |
Why?
|
History, 21st Century | 2 | 2008 | 1573 | 0.100 |
Why?
|
Ethics, Medical | 1 | 2017 | 785 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8747 | 0.100 |
Why?
|
Pain Clinics | 2 | 2016 | 50 | 0.090 |
Why?
|
Adolescent | 12 | 2020 | 89169 | 0.090 |
Why?
|
Communication | 2 | 2022 | 3905 | 0.090 |
Why?
|
Cerebrospinal Fluid Pressure | 1 | 2010 | 38 | 0.090 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 829 | 0.090 |
Why?
|
MELAS Syndrome | 1 | 2011 | 55 | 0.090 |
Why?
|
Risk Factors | 11 | 2012 | 74944 | 0.090 |
Why?
|
Neuroprotective Agents | 2 | 2007 | 958 | 0.090 |
Why?
|
CADASIL | 1 | 2011 | 83 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2005 | 4310 | 0.090 |
Why?
|
History, 20th Century | 2 | 2008 | 2766 | 0.090 |
Why?
|
Ischemic Attack, Transient | 1 | 2015 | 877 | 0.090 |
Why?
|
Demography | 1 | 2014 | 1641 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2197 | 0.080 |
Why?
|
Intracranial Thrombosis | 1 | 2010 | 107 | 0.080 |
Why?
|
Placebos | 4 | 2007 | 1667 | 0.080 |
Why?
|
Women's Health | 1 | 1999 | 2082 | 0.080 |
Why?
|
Patient Admission | 1 | 2017 | 1365 | 0.080 |
Why?
|
Models, Statistical | 1 | 2024 | 5107 | 0.080 |
Why?
|
Coronary Disease | 1 | 2003 | 5919 | 0.080 |
Why?
|
Health Promotion | 1 | 2020 | 2210 | 0.080 |
Why?
|
Sex Factors | 2 | 2020 | 10632 | 0.080 |
Why?
|
Pilot Projects | 3 | 2021 | 8741 | 0.080 |
Why?
|
Neoplasms | 1 | 2017 | 22371 | 0.070 |
Why?
|
Young Adult | 5 | 2020 | 60066 | 0.070 |
Why?
|
Serotonin Antagonists | 1 | 2008 | 147 | 0.070 |
Why?
|
Vasoconstriction | 1 | 2010 | 592 | 0.070 |
Why?
|
Activities of Daily Living | 2 | 2007 | 2430 | 0.070 |
Why?
|
Sex Characteristics | 2 | 2013 | 2649 | 0.070 |
Why?
|
Biofeedback, Psychology | 1 | 2008 | 117 | 0.070 |
Why?
|
Fever | 1 | 2015 | 1614 | 0.070 |
Why?
|
Nerve Block | 1 | 2014 | 716 | 0.070 |
Why?
|
Phytoestrogens | 1 | 2007 | 59 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3384 | 0.070 |
Why?
|
Giant Cell Arteritis | 1 | 2011 | 307 | 0.070 |
Why?
|
Brain Diseases | 1 | 2015 | 1554 | 0.070 |
Why?
|
Sickness Impact Profile | 1 | 2007 | 299 | 0.070 |
Why?
|
Information Storage and Retrieval | 1 | 2012 | 830 | 0.070 |
Why?
|
Acute Disease | 3 | 2007 | 7243 | 0.060 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2008 | 430 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2021 | 1363 | 0.060 |
Why?
|
Program Evaluation | 1 | 2014 | 2507 | 0.060 |
Why?
|
Menstruation Disturbances | 1 | 2007 | 143 | 0.060 |
Why?
|
Progesterone Congeners | 1 | 2005 | 43 | 0.060 |
Why?
|
Polymorphism, Genetic | 2 | 2006 | 4249 | 0.060 |
Why?
|
Neuromuscular Agents | 1 | 2007 | 148 | 0.060 |
Why?
|
Sex Distribution | 2 | 2002 | 2278 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15949 | 0.060 |
Why?
|
Ergotamine | 1 | 2005 | 7 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2018 | 14783 | 0.060 |
Why?
|
Retreatment | 1 | 2007 | 598 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1249 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2011 | 1474 | 0.060 |
Why?
|
Ethinyl Estradiol | 1 | 2005 | 114 | 0.060 |
Why?
|
Lithium | 1 | 2008 | 600 | 0.060 |
Why?
|
Calcium Channel Blockers | 1 | 2008 | 687 | 0.060 |
Why?
|
Therapeutic Equivalency | 1 | 2005 | 134 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 2271 | 0.060 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 42 | 0.060 |
Why?
|
Life Style | 2 | 2008 | 3932 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10590 | 0.060 |
Why?
|
Administration, Intranasal | 1 | 2006 | 485 | 0.060 |
Why?
|
Research | 1 | 2012 | 1979 | 0.060 |
Why?
|
Jurisprudence | 1 | 2004 | 109 | 0.060 |
Why?
|
Methylamines | 1 | 2005 | 136 | 0.060 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2007 | 418 | 0.050 |
Why?
|
Pyrrolidines | 1 | 2005 | 341 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2016 | 10763 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2011 | 1088 | 0.050 |
Why?
|
Age Distribution | 2 | 2015 | 2873 | 0.050 |
Why?
|
Whiplash Injuries | 1 | 2002 | 15 | 0.050 |
Why?
|
Progestins | 1 | 2005 | 302 | 0.050 |
Why?
|
Child | 7 | 2020 | 80917 | 0.050 |
Why?
|
Chronic Disease | 2 | 2010 | 9384 | 0.050 |
Why?
|
Ovary | 1 | 2007 | 965 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1805 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2517 | 0.050 |
Why?
|
Defense Mechanisms | 1 | 2002 | 179 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2020 | 81760 | 0.050 |
Why?
|
Contract Services | 1 | 2002 | 90 | 0.050 |
Why?
|
Drug Therapy | 1 | 2005 | 504 | 0.050 |
Why?
|
Medical History Taking | 1 | 2005 | 779 | 0.050 |
Why?
|
Referral and Consultation | 2 | 2008 | 3620 | 0.050 |
Why?
|
Curriculum | 1 | 2014 | 3782 | 0.050 |
Why?
|
Electric Stimulation Therapy | 1 | 2007 | 635 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2010 | 1255 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2003 | 8542 | 0.050 |
Why?
|
Treatment Failure | 1 | 2007 | 2661 | 0.040 |
Why?
|
Smoking | 1 | 2017 | 9092 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3239 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 4861 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2015 | 3250 | 0.040 |
Why?
|
Inservice Training | 1 | 2003 | 375 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2007 | 1209 | 0.040 |
Why?
|
Aged | 8 | 2020 | 171502 | 0.040 |
Why?
|
Evoked Potentials | 1 | 2006 | 1058 | 0.040 |
Why?
|
Pregnancy Trimester, Third | 1 | 2003 | 587 | 0.040 |
Why?
|
Perception | 2 | 2020 | 1209 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2006 | 15662 | 0.040 |
Why?
|
Time Factors | 5 | 2007 | 40220 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2237 | 0.040 |
Why?
|
Prognosis | 3 | 2024 | 30009 | 0.040 |
Why?
|
Cross-Over Studies | 2 | 2008 | 2107 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2003 | 737 | 0.040 |
Why?
|
Counseling | 1 | 2008 | 1554 | 0.040 |
Why?
|
Recurrence | 2 | 2005 | 8509 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2005 | 905 | 0.040 |
Why?
|
Pain Perception | 1 | 2021 | 198 | 0.040 |
Why?
|
Technology Assessment, Biomedical | 1 | 2022 | 312 | 0.040 |
Why?
|
Physical Examination | 1 | 2005 | 1263 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2663 | 0.040 |
Why?
|
Physicians | 2 | 2013 | 4598 | 0.040 |
Why?
|
Prospective Studies | 5 | 2020 | 54924 | 0.040 |
Why?
|
Research Support as Topic | 1 | 2002 | 696 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1673 | 0.040 |
Why?
|
Boston | 2 | 2016 | 9374 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14729 | 0.030 |
Why?
|
Forecasting | 1 | 2006 | 2945 | 0.030 |
Why?
|
Environment | 1 | 2002 | 1121 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2002 | 939 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 697 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2006 | 2725 | 0.030 |
Why?
|
Emergencies | 1 | 2002 | 1221 | 0.030 |
Why?
|
Neurosurgical Procedures | 1 | 2007 | 2077 | 0.030 |
Why?
|
Empathy | 1 | 2020 | 474 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.030 |
Why?
|
Age of Onset | 1 | 2002 | 3346 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7951 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2018 | 59626 | 0.030 |
Why?
|
Heart Rate | 1 | 2006 | 4214 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2006 | 18065 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13668 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2535 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2016 | 963 | 0.030 |
Why?
|
Culture | 1 | 2017 | 622 | 0.030 |
Why?
|
Military Medicine | 1 | 2015 | 185 | 0.030 |
Why?
|
Health Policy | 2 | 2017 | 2697 | 0.030 |
Why?
|
Health Behavior | 1 | 2004 | 2650 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2003 | 2972 | 0.020 |
Why?
|
Inpatients | 1 | 2003 | 2566 | 0.020 |
Why?
|
Bupivacaine | 1 | 2014 | 414 | 0.020 |
Why?
|
Animals | 3 | 2010 | 169285 | 0.020 |
Why?
|
Blood Pressure | 1 | 2006 | 8543 | 0.020 |
Why?
|
Body Mass Index | 1 | 2007 | 13053 | 0.020 |
Why?
|
Massachusetts | 1 | 2002 | 8890 | 0.020 |
Why?
|
Reference Standards | 1 | 2013 | 1014 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2002 | 3269 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2009 | 11519 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 714 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21207 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2014 | 1005 | 0.020 |
Why?
|
Quality of Life | 3 | 2020 | 13490 | 0.020 |
Why?
|
Clinical Competence | 1 | 2003 | 4858 | 0.020 |
Why?
|
Ohio | 1 | 2007 | 321 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2007 | 556 | 0.020 |
Why?
|
Risk Assessment | 1 | 2007 | 24318 | 0.020 |
Why?
|
Chemoprevention | 1 | 2007 | 327 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2020 | 4530 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2004 | 39354 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12795 | 0.010 |
Why?
|
Acetaminophen | 1 | 2005 | 552 | 0.010 |
Why?
|
Caffeine | 1 | 2005 | 703 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8080 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26379 | 0.010 |
Why?
|
ROC Curve | 1 | 2006 | 3628 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20225 | 0.010 |
Why?
|
Psychometrics | 1 | 2007 | 3063 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3326 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12543 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2001 | 878 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2012 | 5367 | 0.010 |
Why?
|
Aspirin | 1 | 2005 | 3135 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9497 | 0.010 |
Why?
|
Incidence | 1 | 2007 | 21538 | 0.000 |
Why?
|
Depression | 1 | 2008 | 8230 | 0.000 |
Why?
|
Hypertension | 1 | 2008 | 8616 | 0.000 |
Why?
|
Obesity | 1 | 2007 | 13091 | 0.000 |
Why?
|